Aerie Pharmaceuticals Inc (AERI): Are Hedge Funds Right About This Stock?
Aerie Looks to Japanese Market for Eye Drug, Opens Tokyo Office | North Carolina Biotechnology Center
Our Eye Care Products | Aerie Pharmaceuticals, Inc.
Analysts Offer Insights on Healthcare Companies: Cooper Co (NYSE: COO) and Aerie Pharma (NASDAQ: AERI) - Markets
Research & Development | Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals Inc - ZIP 27703, NAICS 423450
Investor Relations | Aerie Pharmaceuticals, Inc
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps - Ophthalmology Innovation Summit - OIS
Aerie Pharma (AERI) Falls on Glaucoma Eye Drop Safety Concerns - TheStreet
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
Aerie Pharmaceuticals Employees, Location, Careers | LinkedIn
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharma (AERI) Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Aerie Pharmaceuticals (Nasdaq: AERI) acquires Spanish company Avizorex Pharma - Triangle Business Journal
Aerie Pharmaceuticals Inc 2021 Current Report 8-K
Xconomy: Aerie Pharma Eyes $58M IPO For Glaucoma Drug Push
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Aerie Pharma appoints Richard Rubino as CFO
Investor Relations | Aerie Pharmaceuticals, Inc
Casey Kopczynski - Chief Scientific Officer and Founder - Aerie Pharmaceuticals, Inc | LinkedIn
